Lipoic Acid for Progressive Multiple Sclerosis (MS)

PHASE2CompletedINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

August 17, 2018

Primary Completion Date

December 31, 2023

Study Completion Date

June 30, 2024

Conditions
Multiple Sclerosis
Interventions
DRUG

Lipoic acid

1200 mg taken by mouth daily for two years starting on day one of the study and ending on the last day of study participation.

DRUG

Placebo

The placebo comparator will be taken by mouth daily for two years starting on day one of the study and ending on the last day of study participation

Trial Locations (11)

20422

Washington DC VA Medical Center, Washington, DC, Washington D.C.

35294

University of Alabama at Birmingham, Birmingham

75216

VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas

80045

University of Colorado, Aurora

84148

University of Utah, Salt Lake City

VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City

98108

VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle

98122

Swedish Medical Center, Seattle

97207-2964

VA Portland Health Care System, Portland, OR, Portland

05401

University of Vermont, Burlington

K1Y 4E9

Ottawa Hospital Research Institute, Ottawa

All Listed Sponsors
lead

VA Office of Research and Development

FED

NCT03161028 - Lipoic Acid for Progressive Multiple Sclerosis (MS) | Biotech Hunter | Biotech Hunter